Secondary Navigation Menu

Audience Switcher Modal

Country and Audience Choose Modal

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

Scientific Congress Publications

Supported by Bayer Pharmaceuticals

ISC 2026

Factor XIa Inhibition With Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial ​
Date/Time:
Thursday, February 5, 2026 / 11:00 AM – 12:30 PM, CST
Presenting Author:
Mukul Sharma
Presentation Session:
ISC Invited Symposium
Qualifying Ischemic Stroke Subtypes and Response to Asundexian: Prespecified Secondary Analysis of the OCEANIC-STROKE Trial
Date/Time:
Thursday, February 5, 2026 / 3:45 PM – 4:55 PM, CST
Presenting Author:
Ashkan Shoamanesh
Presentation Session: ​
Oral Abstract Session
Understanding the Lived Experiences of Primary and Recurrent Stroke Survivors in the United States, with a Focus on Women: the ELEVATE Qualitative Study​
Date/Time:
Tuesday, February 3, 2026 / 1:30 PM – 3:30 PM, CST
Presenting Author:
Caitie Zavila
Poster Session: ​
Pre-Con Symposium - HEADS-UP
Real-World Assessment of Healthcare Resource Utilization and Expenditures Following Initial Ischemic Stroke or Transient Ischemic Attack of Non-Cardioembolic Origin​
Date/Time:
Thursday, February 5, 2026 / 12:30 PM – 2:30 PM, CST
Presenting Author:
Emily Durden
Poster Session: ​
Poster Abstract Session
Characteristics and Outcomes of the Real-World Cohort of Patients With Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack Compatible With the OCEANIC-STROKE Clinical Trial Population in Japan
Date/Time:
Thursday, February 5, 2026 / 12:30 PM – 2:30 PM, CST
Presenting Author:
Teruyuki Hirano
Poster Session: ​
Moderated Digital Oral Abstracts